Literature DB >> 16856014

Quinolones for uncomplicated acute cystitis in women.

V Rafalsky1, I Andreeva, E Rjabkova.   

Abstract

BACKGROUND: Uncomplicated acute cystitis is one of the most common bacterial infections in adults. The percentage of women who have at least one episode of acute cystitis is estimated to be between 40% to 50%. Quinolones are recommended for acute cystitis in regions where the level of resistance to other antimicrobials namely co-trimoxazole is high. However the efficacy, safety and tolerance of quinolones needs investigation.
OBJECTIVES: To compare the efficacy, safety and tolerance of different quinolones in women with uncomplicated acute cystitis. SEARCH STRATEGY: We searched the Cochrane Central Register of Controlled Trials (CENTRAL, in The Cochrane Library Issue 3, 2003), MEDLINE (1966 - September 2003), EMBASE (1988 - September 2003), reference lists of articles and abstracts from conference proceedings without language restriction. Reference lists of urology, infectious diseases and nephrology textbooks, review articles and relevant studies. SELECTION CRITERIA: Randomised and quasi-randomised controlled trials comparing two or more different quinolones in women (>/= 16 years) with uncomplicated acute cystitis were selected. DATA COLLECTION AND ANALYSIS: Two reviewers independently assessed trial quality and extracted data. Statistical analyses were performed using the random effects model and the results expressed as relative risk (RR) for dichotomous outcomes with 95% confidence intervals (CI). MAIN
RESULTS: We identified 11 studies enrolling 7535 women. There were no significant differences in clinical or microbiological efficacy between quinolones. Photosensitivity reactions were more frequently observed for sparfloxacin when compared to ofloxacin. Any adverse event, adverse events causing withdrawal, skin adverse events, photosensitivity reactions were more common for lomefloxacin when compared to norfloxacin. Any adverse event, adverse drug reactions, CNS adverse events were more common for ofloxacin when compared to ciprofloxacin. CNS adverse events and insomnia were more often reported for rufloxacin when compared to pefloxacin. Adverse drug reactions occurred frequently for ofloxacin than levofloxacin. Insomnia was reported more frequently for enoxacin than ciprofloxacin. AUTHORS'
CONCLUSIONS: We found no significant differences in clinical or microbiological efficacy between quinolones but some differences in occurrence and spectrum of quinolone safety.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16856014      PMCID: PMC7003573          DOI: 10.1002/14651858.CD003597.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  91 in total

Review 1.  Review of norfloxacin in lower urinary tract infections.

Authors:  L Miano; S Goldoni; A Tubaro; G Paradiso Galatioto; P Gandolfi
Journal:  Eur Urol       Date:  1990       Impact factor: 20.096

2.  Comparative efficacies of oral pefloxacin in uncomplicated cystitis. Single dose or 3-day therapy.

Authors:  A Leelarasamee; I Leelarasamee
Journal:  Drugs       Date:  1995       Impact factor: 9.546

3.  Urinary tract infection in adults: research priorities and strategies.

Authors:  A R Ronald; L E Nicolle; E Stamm; J Krieger; J Warren; A Schaeffer; K G Naber; T M Hooton; J Johnson; S Chambers; V Andriole
Journal:  Int J Antimicrob Agents       Date:  2001-04       Impact factor: 5.283

4.  Single-dose pefloxacin versus five-days treatment with norfloxacin in uncomplicated cystitis in women.

Authors:  F A van Balen; F W Touw-Otten; R A de Melker
Journal:  J Antimicrob Chemother       Date:  1990-10       Impact factor: 5.790

Review 5.  Short-term therapy of acute uncomplicated cystitis.

Authors:  K G Naber
Journal:  Curr Opin Urol       Date:  1999-01       Impact factor: 2.309

6.  Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy.

Authors:  C E Cox; J R Simmons
Journal:  South Med J       Date:  1982-05       Impact factor: 0.954

7.  A comparison between single-dose fosfomycin trometamol (Monuril) and a 5-day course of trimethoprim in the treatment of uncomplicated lower urinary tract infection in women.

Authors:  M A Minassian; D A Lewis; D Chattopadhyay; B Bovill; G J Duckworth; J D Williams
Journal:  Int J Antimicrob Agents       Date:  1998-04       Impact factor: 5.283

8.  Pefloxacin single-dose in the treatment of acute uncomplicated lower urinary tract infections in women: a meta-analysis of seven clinical trials.

Authors:  K G Naber; W Baurecht; M Fischer; M Kresken
Journal:  Int J Antimicrob Agents       Date:  1994-08       Impact factor: 5.283

9.  Experience with ciprofloxacin in vitro and in vivo.

Authors:  H Giamarellou; A Efstratiou; J Tsagarakis; G Petrikkos; G K Daikos
Journal:  Arzneimittelforschung       Date:  1984

10.  The U.S. clinical experience with lomefloxacin, a new once-daily fluoroquinolone.

Authors:  E Rizk
Journal:  Am J Med       Date:  1992-04-06       Impact factor: 4.965

View more
  13 in total

1.  Symptomatic treatment (ibuprofen) or antibiotics (ciprofloxacin) for uncomplicated urinary tract infection?--results of a randomized controlled pilot trial.

Authors:  Jutta Bleidorn; Ildikó Gágyor; Michael M Kochen; Karl Wegscheider; Eva Hummers-Pradier
Journal:  BMC Med       Date:  2010-05-26       Impact factor: 8.775

2.  Fluorimetric study on the interaction between Norfloxacin and Proflavine hemisulphate.

Authors:  Vishalkumar R More; Prashant V Anbhule; Sang H Lee; Shivajirao R Patil; Govind B Kolekar
Journal:  J Fluoresc       Date:  2011-03-30       Impact factor: 2.217

Review 3.  Quinolones for uncomplicated acute cystitis in women.

Authors:  V Rafalsky; I Andreeva; E Rjabkova
Journal:  Cochrane Database Syst Rev       Date:  2006-07-19

4.  Uncomplicated urinary tract infections.

Authors:  Florian M E Wagenlehner; Udo Hoyme; Martin Kaase; Reinhard Fünfstück; Kurt G Naber; Guido Schmiemann
Journal:  Dtsch Arztebl Int       Date:  2011-06-17       Impact factor: 5.594

5.  Periodontitis in rats induces systemic oxidative stress that is controlled by bone-targeted antiresorptives.

Authors:  Sehkar Oktay; Sasanka S Chukkapalli; Mercedes F Rivera-Kweh; Irina M Velsko; L Shannon Holliday; Lakshmyya Kesavalu
Journal:  J Periodontol       Date:  2015-01       Impact factor: 6.993

Review 6.  Rational identification of enoxacin as a novel V-ATPase-directed osteoclast inhibitor.

Authors:  Edgardo J Toro; David A Ostrov; Thomas J Wronski; L Shannon Holliday
Journal:  Curr Protein Pept Sci       Date:  2012-03       Impact factor: 3.272

7.  What should urologists know about evidence-based medicine?

Authors:  Jan W Mazel; Rudolf W Poolman
Journal:  Indian J Urol       Date:  2011-10

8.  A New Tool for in vivo Manipulation of Brain microRNA Levels: The Work of Smalheiser et al. (2014).

Authors:  Don A Baldwin
Journal:  Front Psychiatry       Date:  2015-04-20       Impact factor: 4.157

9.  Norfloxacin--toxicity for Zebrafish (Danio rerio) focused on oxidative stress parameters.

Authors:  Marta Bartoskova; Radka Dobsikova; Vlasta Stancova; Ondrej Pana; Dana Zivna; Lucie Plhalova; Jana Blahova; Petr Marsalek
Journal:  Biomed Res Int       Date:  2014-03-13       Impact factor: 3.411

10.  Role of symbiotic bacteria in the growth and development of the Sunn pest, Eurygaster integriceps.

Authors:  Maryam Kafil; Ali Reza Bandani; Martin Kaltenpoth; Seyed Hossein Goldansaz; Seyed Mehdi Alavi
Journal:  J Insect Sci       Date:  2013       Impact factor: 1.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.